# SMART Study: A Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on Anti-TNF Alfa Therapy

> **NCT01126541** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 224 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** rituximab

## Key facts

- **NCT ID:** NCT01126541
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 224 (ACTUAL)
- **Last updated:** 2014-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01126541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01126541, "SMART Study: A Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on Anti-TNF Alfa Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01126541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*